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Haemostasis is the human body’s response to blood vessel injury and bleeding. 
It involves a coordinated effort between vessel wall, platelets and numerous blood 
clotting proteins (or factors), resulting in the formation of a blood clot and subsequent 
stopping of the bleed 1.
Coagulation begins almost instantly after an injury has damaged the endothelium 
of the vessel. Exposure of blood to the subendothelium initiates two processes: 
changes in platelets, and exposure of subendothelial tissue factor (TF) to plasma 
factor VII, which ultimately leads to fibrin formation. Platelets immediately form a 
plug at the site of injury. Simultaneously, different coagulation factors respond in a 
complex cascade to form fibrin strands (see figure 1A) 2, which strengthen the platelet 
plug 3. The coagulation cascade leads to fibrin formation. 
Coagulation
Coagulation is initiated by the exposure of cell membrane bound TF to plasma 
factor VIIa and activation of factor VII (FVIIa). The TF-FVIIa complex binds and activates 
factor X (FXa) rapidly and small amounts of thrombin (IIa) are formed with coagulation 
factor V as a cofactor. The TF-FVIIa complex also binds and activates  factor IX (IXa) 
leading to increased activation of Xa and enhanced generation of thrombin. Thrombin 
then activates factor XI (FXIa), FXIa activates factor IX (FIXa) with co-factor FVIIIa 
(tenase complex), which activates FX to FXa. This small amount of thrombin can then 
activate more factor XI, amplifying the response which leads to the formation of fibrin 
monomers. These monomers can be crosslinked by coagulation factor XIII and result 
in a stabilised haemostatic plug 2, 4-7 (see figure 1A). High concentrations of thrombin 
also give feedback inhibition of the coagulation system by activation, together with 








made a fly wheel model which includes the important role of coagulation factor XI in both amplification 
of the thrombin formation and the downregulations of fibrinolysis (Figure 1A). In Figure 1B a simplification of fibrinolysis. 
Legend: IIa: thrombin; IXa+VIII: factor IXa and VIII (depicting the tenase complex); IXa: Factor IX activated; Xa + V: factor Xa and 
V (depicting the prothrombinase complex); XIa: Factor XI activated; APC activated protein C; FDP: fibrin degradation products; 
PAI-1: plasminogen activator inhibitor-1; PI: plasmin inhibitor; TAFI: thrombin-activatable fibrinolysis inhibitor; TFPI: tissue factor 
pathway inhibitor; TF-VIIa: tissue factor-factor VIIa complex; TM: thrombomodulin; t-PA: tissue plasminogen activator. 
Fibrinolysis
Fibrinolysis is the process that prevents blood clots from growing and becoming 
problematic 8. In fibrinolysis, a fibrin clot, the product of coagulation, is broken down 
9 (figure 1B). Its main enzyme plasmin cuts the fibrin in fragments that are cleared 
by other proteases and cleared by the kidney and liver. Plasmin is produced in an 
inactive form, plasminogen, in the liver. Although plasminogen cannot cleave fibrin, 
it still has an affinity for it, and is incorporated into the clot when it is formed. Tissue 
plasminogen activator (t-PA) and urokinase are agents that convert plasminogen to 
active plasmin, thus allowing fibrinolysis to occur 1. t-PA is very slowly released into 
the blood by damaged endothelium, such that, after several days (when the bleeding 
is stopped) the clot is broken down. This occurs because plasminogen, entrapped 
within the clot when formed, is slowly activated to break down the fibrin mesh. t-PA 
and urokinase are themselves inhibited by plasminogen activator inhibitor-1 (PAI-1) 
and plasminogen activator inhibitor-2 (PAI-2).  Plasmin itself is inhibited by several 
inhibitors, including alpha 2- antiplasmin/ plasmin inhibitor (PI), alpha 2-macroglobulin 
and the thrombin-activatable fibrinolysis inhibitor (TAFI). TAFI modifies fibrin to make 
it more resistant to the t-PA-mediated plasminogen. 
Generally, in healthy people without bleeding disorders, control of bleeding is 
achieved very quickly and without the need for medical treatment. In major trauma 
or surgery, doctors often need to help patients to reach normal haemostasis in order 
to minimise blood loss and further injury.
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Factor XI
FXI deficiency, also known as haemophilia C, is an autosomal bleeding disorder 
characterized by reduced levels of FXI in plasma. Homozygote FXI deficients (about 
1:450) are rare 10. The heterozygous state has a high prevalence (about 1:11) in the 
Ashkenazi Jewish population 11. The prevalence of FXI deficiency in Caucasians is 
reported as low, but might be underestimated 12, 13. Bleeding manifestations are not 
well correlated with the plasma levels of FXI activity and bleeding episodes can vary 
widely among patients with similar FXI levels 11, 14. FXI-deficient patients present with 
an injury-related bleeding tendency 15, which can be explained by different roles of 
FXI in the coagulation cascade. Following activation by the contact factor or tissue 
factor pathways, the coagulation cascade is maintained in prothrombotic state by 
the continued activation of FVIII and FIX to form the tenase complex, until it is down-
regulated by the anticoagulant pathways 16, 17.  FXI can also be activated by thrombin 
and FXI is not only a procoagulant, but also an antifibrinolytic factor by TAFI as the 
mediator of the antifibrinolytic activity of FXI. Factor XI deficient patients are prone 
to bleeding from tissues with a high fibrinolytic activity (urinary/gynaecological tract, 
nose or oral cavity), and it is at these sites that the downregulation of fibrinolysis is 
not provided for the factor XI dependent generation of thrombin and TAFI activation. 
Menstruation
Menstruation is an intrinsic haemostatic challenge to women. The most obvious 
manifestation of the normal menstruation cycle is the presence of regular menstrual 
periods. These occur as the endometrium is shed following failure of implementation 
of fertilization of the oocyte. Menstruation is initiated in response to changes in 
steroids produced by the ovaries, which themselves are controlled by the pituitary 
and hypothalamus. Within the ovary, the menstrual cycle can be divided into three 
phases. In the first, follicular, phase the development of the oocyte is stimulated by 
pituitary hormones (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). 
The second phase is the ovulation. Ovulation typically takes place around the 13th 






the corpus luteum remains behind in the ovary. The luteal phase is characterized 
by the production of progesterone from the corpus luteum within the ovary. As the 
corpus luteum dies at the end of the luteal phase, circulating levels of oestrogen and 
progesterone fall precipitously. During this luteal phase the endometrium becomes 
decidualized and allows implantation of the embryo. Decidualization is an irreversible 
process, and if implantation does not occur, apoptosis ensues. Menstruation is the 
shedding of the ‘dead’ endometrium and ceases as the endometrium regenerates. 
Normal menstruation can be described in part as a haemostatic process given the 
necessity for monthly formation of a primary platelet aggregate with subsequent 
secondary fibrin formation with concurrent fibrinolytic modeling of the fibrin clot. 
When this process is out of balance, heavy menstrual bleeding can appear. 
Heavy menstrual bleeding is a major health problem, affecting about 10% of 
all premenopausal women and in approximately 2.5% of women even leading to 
iron deficiency anaemia 18. Internationally, heavy menstrual bleeding is defined as 
greater than or equal to 80 ml blood loss per menstrual cycle 19, which is considered 
equivalent to a Pictorial Bleeding Assessment Chart (PBAC) score of 100 points 20. For 
daily gynaecological practice the Dutch guidelines for Gynaecologists have chosen 
a PBAC score  of around 150 as the most suitable cut-off point with corresponding 
sensitivity of 78-83% and specificity of 77-88% 21, 22. Heavy menstrual bleeding can 
affect a woman’s quality of life, her study or work and family and social interaction 23. 
Systemic causes of heavy menstrual bleeding
Women who are referred for heavy menstrual bleeding can have many different 
causes for this symptom. We included patients for our study on systemic causes for 
heavy menstrual bleeding from March 2007 till May 2015 at the one-stop outpatient 
clinic in the University Medical Centre of Groningen. Knol et al. previously published 
on prevalence of coagulation disorders in a part of this cohort  24, this were patients 
included from March 2007 till December 2010. The study of systemic fibrinolysis 
in women with heavy menstrual bleeding took place in this same subgroup. The 
confirmation of the low FXI levels Knol found in her study 24 was performed in the 
patients enrolled in the period from December 2010 till May 2015. The study with SNV 
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and mutations of FXI include a part of the patients included between December 2010 
till May 2015. The study of thyroid dysfunction and heavy menstrual bleeding and the 
screening tool study include all patients.  
Heavy menstrual bleeding can be caused by abnormal blood clotting, disruption 
of normal hormonal regulation of periods, or disorders of the endometrial lining of 
the uterus. 
Abnormal blood clotting can be a manifestation of a wide range of haemostatic 
disorders 25, 26. Von Willebrand’s disease (VWD) has been recognized as an important 
etiologic or contributory factor 27, but platelet dysfunction and low factor XI levels are 
also prevalent 24, 28. 
It would be efficient and decrease costs if one could predict better who should be 
tested for bleeding disorders. A screening tool is needed. There is only one published 
screening tool for bleeding disorders in women with heavy menstrual bleeding 
developed and validated by Philipp et al. 29, 30. Despite good sensitivity, the Philipp tool 
did not adequately discriminate in both of her studies, as demonstrated by likelihood 
ratios that were close to one.
Factor XI deficient individuals are prone to bleed excessively during and/or 
after surgery and particularly in areas of high fibrinolysis such as the mouth and 
genitourinary system 31, 32. Bleeding manifestations are not well correlated with the 
plasma levels of FXI activity and bleeding episodes can vary widely among patients 
with similar FXI levels 11, 33. Heavy menstrual bleeding is reported in a wide range (7-
67%) of women with FXI deficiency 34-41.
Another cause of heavy menstrual bleeding can be found in the endometrial 
lining of the uterus. The fibrinolysis in the endometrium plays an important role in 
menstruation. In women with heavy menstrual bleeding, increased fibrinolytic activity 
was observed in the menstrual fluid, which suggests that this might be a contributory 
factor in the etiology of heavy menstrual bleeding 42, 43. Moreover, antifibrinolytic 
agents, such as tranexamic acid, are effective in reducing menstrual blood loss 44, 45. 
Notably, the role of systemic fibrinolysis in women with heavy menstrual bleeding has 
not been studied. 






bleeding. Thyroid disease is the second most common endocrine disease in women 
of reproductive age and has long been linked to menstrual disturbances 46. Thyroid 
stimulating hormone has both follicle-stimulating hormone and luteinizing hormone-
like effects through their shared α–subunit. As a result, negative feedback is down-
regulated, leading to a decreased secretion of luteinizing hormone and an ensuing 
decrease in progesterone. At the same time, decreased sex hormone binding globulin 
results in increased serum estriol and unbound estradiol, which in turn leads to 
elevated levels of circulating free estrogens. This prolonged, unopposed effect on 
the endometrium can result in failure of anovulation and corpus luteum formation, 
ultimately leading to menometrorrhagia 46, 47. Several studies have been performed 
on thyroid function and menstrual blood loss, but no objective measurements of 
menstrual blood loss were reported or the sample sizes were small 47-49. As a result, 
conflicting opinions were issued about measuring the thyroid function in women 
with heavy menstrual bleeding 50-53. An explanation for the discrepancy between the 
various guidelines could be the lack of good quality evidence of the role of thyroid 
function in heavy menstrual bleeding. 
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Outline of this thesis
This thesis focuses on systemic causes of gynaecological bleeding problems in 
women. In Chapter 2 we test the screening tool of Philipp in a new cohort of women 
with heavy menstrual bleeding. Because this screening tool did not perform well, we 
developed a new screening tool for bleeding disorders in women with heavy menstrual 
bleeding. Chapter 3 investigates the factor XI levels and levels of other coagulation 
factors in women with heavy menstrual bleeding. In Chapter 4, the factor 11 gene 
is analysed in women with heavy menstrual bleeding. In Chapter 5 we test whether 
that increased systemic fibrinolysis might contribute to heavy menstrual bleeding. In 
Chapter 6 we study thyroid function in a large cohort of women with heavy menstrual 
bleeding with validated measurements of blood loss, gynaecological examination 
and analysis of other systemic causes of heavy menstrual bleeding. We compare the 
prevalence of thyroid dysfunction in women with heavy menstrual bleeding with that 
in the general population. In Chapter 7 a family with factor XI deficiency is presented, 
where the diversity of presentation of this disease is demonstrated. In Chapter 8 we 
summarize the incidence of gynaecological and obstetrical bleeding in women with 
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